Category - Developments

Developments

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

BeyondSpring (NASDAQ: BYSI) presented a poster of the design for its Phase 3 Study 103 at the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain on Sept. 9. Study 103 is a multi-center...

September 10, 2019

Developments

Zenabis to supply recreational cannabis to Ontario retail outlets

Zenabis Global (TSX:ZENA) inked a supply agreement with the Ontario Cannabis Retail Corp. (OCS) to supply adult-use recreational cannabis to retailers throughout the province. Zenabis will begin supplying OCS with 21...

September 10, 2019

Developments

Toronto Innovation Acceleration Partners in pact with Amgen

Toronto Innovation Acceleration Partners (TIAP), formerly MaRS Innovation, and Amgen (NASDAQ:AMGN) are collaborating to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member...

September 9, 2019

Developments

Soricimed, Image Analysis Group to validate SOR-C13 imaging markers

Soricimed Biopharma entered into a strategic alliance with Image Analysis Group for the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. Image...

September 6, 2019

Developments

NEJM landmark cardiac study included genetic testing with Spartan Bioscience rapid genotyping system

The New England Journal of Medicine published results from a landmark clinical trial called, “Patient Outcome after Primary PCI” (POPular Genetics), that included genetic testing using the Spartan RX CYP2C19 rapid...

September 5, 2019

Developments

Precipio and U of Penn in joint pathology diagnostics collaboration

Precipio (NASDAQ:PRPO) inked a new joint collaboration with the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania to expand cancer patient access to...

September 5, 2019

Developments

Versant Ventures launches medtech sector investment firm

Versant Ventures launched an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with...

September 5, 2019

Developments

Aerie Pharma upsizes and prices private sale of $275-million of convertible notes

Aerie Pharmaceuticals (NASDAQ:AERI) priced $275-million principal amount of 1.5% convertible senior notes due 2024. The offering was increased to $275-million from a previously announced size of $250-million. The notes...

September 5, 2019

Developments

Repare Therapeutics raises $82.5-million in Series B financing

Closely-held Repare Therapeutics completed an $82.5-million Series B financing as it prepares to take its lead synthetic lethality therapy into human testing in 2020. Cowen Healthcare Investments led the financing and...

September 4, 2019

Developments

Paratek Pharma’s Phase 3 NUZYRA trial results published in The Lancet Infectious Diseases

The results of Paratek Pharmaceuticals’ (NASDAQ:PRTK) Phase 3 trial of NUZYRA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) have been published in the peer-reviewed journal, The Lancet...

August 30, 2019

Category - Developments

Subscribe